Biotechnology News

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, to...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuros...

LIVERMORE, Calif., & TAIPEI, Taiwan--(BUSINESS WIRE)--Syncell announced the commercial launch of Syncell Discovery Services, a global sample-to-discovery program powered by the Microscoop Mint platform...

BOSTON--(BUSINESS WIRE)--Ontada will present a real-world research study at the ASCO Annual Meeting examining GLP-1 receptor agonist utilization and overall survival outcomes....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe presents late-breaking preclinical data supporting STX-1150, a clinical-stage epigenetic silencing therapy...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...

NEW YORK--(BUSINESS WIRE)--Real Chemistry announced the appointments of two non-executive board members, Frank Clyburn and Christopher Fikry, M.D....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI®, the real‑world healthcare intelligence company for those advancing research, treatment, and care in oncology and other complex diseases, is unveiling enhancements to its CancerLinQ® Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The new capabilities leverage clinically intelligent AI to parse through large volumes of structured and unstructured data on a weekly basis, giving oncologists and clinical care teams faster...